Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, ...

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.

Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired ...

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...

Excellus BlueCross BlueShield is pushing back against reports that it will no longer cover GLP-1 medications, saying drugs ...

Patients often don’t realize that the same procedure at different locations (even with the same insurance) can have very different out-of-pocket costs.

Purdue switched its pharmacy benefit manager from CVS Caremark to AffirmedRx, citing more transparency for drug costs.

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up ...

Dr. Eithan Haim has said publicly that he leaked the documents to a conservative activist in 2023 to “expose” care that he ...